These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 27793896)
1. ITPP Treatment of RG2 Glioblastoma in a Rat Model. Förnvik K; Zolfaghari S; Salford LG; Redebrandt HN Anticancer Res; 2016 Nov; 36(11):5751-5755. PubMed ID: 27793896 [TBL] [Abstract][Full Text] [Related]
2. Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice. Iyengar S; Schwartz D Anticancer Res; 2017 Mar; 37(3):1121-1125. PubMed ID: 28314273 [TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic properties of myo-inositol trispyrophosphate in ovo and growth reduction of implanted glioma. Sihn G; Walter T; Klein JC; Queguiner I; Iwao H; Nicolau C; Lehn JM; Corvol P; Gasc JM FEBS Lett; 2007 Mar; 581(5):962-6. PubMed ID: 17316624 [TBL] [Abstract][Full Text] [Related]
4. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. Tran LB; Cao-Pham TT; Jordan BF; Deschoemaeker S; Heyerick A; Gallez B J Cell Mol Med; 2019 Mar; 23(3):1908-1916. PubMed ID: 30575283 [TBL] [Abstract][Full Text] [Related]
5. Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate. Limani P; Linecker M; Kachaylo E; Tschuor C; Kron P; Schlegel A; Ungethuem U; Jang JH; Georgiopoulou S; Nicolau C; Lehn JM; Graf R; Humar B; Clavien PA Clin Cancer Res; 2016 Dec; 22(23):5887-5897. PubMed ID: 27489288 [TBL] [Abstract][Full Text] [Related]
6. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1α suppression and eradication of early hepatoma tumors in rats. Aprahamian M; Bour G; Akladios CY; Fylaktakidou K; Greferath R; Soler L; Marescaux J; Egly JM; Lehn JM; Nicolau C Chembiochem; 2011 Mar; 12(5):777-83. PubMed ID: 21370375 [TBL] [Abstract][Full Text] [Related]
7. Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response. El Hafny-Rahbi B; Brodaczewska K; Collet G; Majewska A; Klimkiewicz K; Delalande A; Grillon C; Kieda C J Cell Mol Med; 2021 Apr; 25(7):3284-3299. PubMed ID: 33624446 [TBL] [Abstract][Full Text] [Related]
8. The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in Mice. Limani P; Linecker M; Schneider MA; Kron P; Tschuor C; Kachaylo E; Ungethuem U; Nicolau C; Lehn JM; Graf R; Humar B; Clavien PA Ann Surg; 2017 Nov; 266(5):746-753. PubMed ID: 28742687 [TBL] [Abstract][Full Text] [Related]
9. Combined endogenous MR biomarkers to assess changes in tumor oxygenation induced by an allosteric effector of hemoglobin. Cao-Pham TT; Tran-Ly-Binh A; Heyerick A; Fillée C; Joudiou N; Gallez B; Jordan BF NMR Biomed; 2020 Feb; 33(2):e4181. PubMed ID: 31762121 [TBL] [Abstract][Full Text] [Related]
10. Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. Schneider MA; Linecker M; Fritsch R; Muehlematter UJ; Stocker D; Pestalozzi B; Samaras P; Jetter A; Kron P; Petrowsky H; Nicolau C; Lehn JM; Humar B; Graf R; Clavien PA; Limani P Nat Commun; 2021 Jun; 12(1):3807. PubMed ID: 34155211 [TBL] [Abstract][Full Text] [Related]
11. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. Biolo A; Greferath R; Siwik DA; Qin F; Valsky E; Fylaktakidou KC; Pothukanuri S; Duarte CD; Schwarz RP; Lehn JM; Nicolau C; Colucci WS Proc Natl Acad Sci U S A; 2009 Feb; 106(6):1926-9. PubMed ID: 19204295 [TBL] [Abstract][Full Text] [Related]
12. Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes. Görgens C; Guddat S; Schänzer W; Thevis M Drug Test Anal; 2014; 6(11-12):1102-7. PubMed ID: 25070041 [TBL] [Abstract][Full Text] [Related]
13. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Kieda C; Greferath R; Crola da Silva C; Fylaktakidou KC; Lehn JM; Nicolau C Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15576-81. PubMed ID: 17028170 [TBL] [Abstract][Full Text] [Related]
14. [Enhanced metastatic potential of rat RG2 glioblastoma cells transfected with CD44v (meta-1) sequence]. Li H; Hofmann M; Liu J Zhonghua Zhong Liu Za Zhi; 1996 Sep; 18(5):343-6. PubMed ID: 9387271 [TBL] [Abstract][Full Text] [Related]
15. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. Oknińska M; El-Hafny-Rahbi B; Paterek A; Mackiewicz U; Crola-Da Silva C; Brodaczewska K; Mączewski M; Kieda C J Cell Mol Med; 2020 Feb; 24(3):2272-2283. PubMed ID: 31957267 [TBL] [Abstract][Full Text] [Related]
16. Development of a methodology for in vivo follow-up of hepatocellular carcinoma in hepatocyte specific Trim24-null mice treated with myo-inositol trispyrophosphate. Ignat M; Akladios CY; Lindner V; Khetchoumian K; Teletin M; Muttter D; Aprahamian PM; Marescaux J J Exp Clin Cancer Res; 2016 Sep; 35(1):155. PubMed ID: 27686696 [TBL] [Abstract][Full Text] [Related]
17. Detection of myo-inositol trispyrophosphate in equine urine and plasma by hydrophillic interaction chromatography-tandem mass spectrometry. Wong AS; Ho EN; Wan TS Drug Test Anal; 2012 May; 4(5):355-61. PubMed ID: 22359395 [TBL] [Abstract][Full Text] [Related]